Global Parkinson Disease Market Projected to Reach $8.8 Billion by 2030, Driven by Advancements and Growing Demand for Effective Treatments
March 28, 2024 11:41 ET
|
Research and Markets
Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Parkinson Disease Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. ...
Global $481 Million Motion Sickness Treatment Market, 2023-2029: Rising Demand Among Millennial Travelers for Distinctive & Exclusive Travel Experiences Driving the Market
June 26, 2023 05:18 ET
|
Research and Markets
Dublin, June 26, 2023 (GLOBE NEWSWIRE) -- The Global Motion Sickness Treatment Market, 2023-2029 report has been added to ResearchAndMarkets.com's offering.The Global Motion Sickness Treatment...
Global Cerebral Palsy Treatment Market Report to 2030 - Featuring Merz Pharmaceuticals, Pfizer, Bayer and Johnson & Johnson Among Others
May 16, 2022 07:13 ET
|
Research and Markets
Dublin, May 16, 2022 (GLOBE NEWSWIRE) -- The "Cerebral Palsy Treatment Market by Drug Type, Disease Type, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030" report...
2021 U.S. Parkinson's Disease Epidemiology Report: 10-year Forecasts of Parkinson's Disease Epidemiology
August 23, 2021 04:18 ET
|
Research and Markets
Dublin, Aug. 23, 2021 (GLOBE NEWSWIRE) -- The "Parkinson's Disease - US Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. The report delivers an...
Newly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
June 26, 2017 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Announces Appointment of Ian Clements as Vice President, Investor Relations
June 06, 2017 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Present at Jefferies 2017 Global Healthcare Conference
May 30, 2017 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Announces Closing of 3.00% Convertible Senior Notes Offering
May 16, 2017 16:01 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the closing of its previously announced offering of 3.00% Convertible Senior Notes due 2022 (the...
Dermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes
May 10, 2017 21:32 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 3.00% Convertible Senior...
Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
May 09, 2017 16:01 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today that it intends to offer, subject to market conditions and other factors, $250,000,000 aggregate...